Circulating tumor DNA for personalized lung cancer monitoring

Advances in deep sequencing technology have led to developments in personalized medicine. Here, we describe the implications of a recent investigation that sequenced ctDNA from the plasma of non-small cell lung cancer patients to develop personalized ctDNA tests. These ‘liquid biopsies’ have shown p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiala, Clare, Diamandis, Eleftherios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559853/
https://www.ncbi.nlm.nih.gov/pubmed/28814291
http://dx.doi.org/10.1186/s12916-017-0921-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559853/
https://www.ncbi.nlm.nih.gov/pubmed/28814291
http://dx.doi.org/10.1186/s12916-017-0921-6

Ejemplares similares